FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275273709> ?p ?o ?g. }

• W2275273709 endingPage "147" @default.
• W2275273709 startingPage "138" @default.
• W2275273709 abstract "The purpose of this study was to characterize outcomes for everolimus-eluting stent (EES)-treated subjects according to treatment with continued thienopyridine plus aspirin versus aspirin alone 12 to 30 months after stenting.In the DAPT (Dual Antiplatelet Therapy) study, continued thienopyridine plus aspirin beyond 1 year after coronary stenting reduced ischemic events. Given low rates of stent thrombosis and myocardial infarction (MI) for current drug-eluting stents, we examined outcomes among EES-treated subjects in the DAPT study.The DAPT study enrolled 25,682 subjects (11,308 EES-treated) after coronary stenting. Following 12 months of treatment with thienopyridine and aspirin, eligible subjects continued treatment with aspirin and 9,961 (4,703 with EES) were randomized to 18 months of continued thienopyridine or placebo. Stent type was not randomized, and the EES subset analysis was post hoc.Among EES-treated patients, continued thienopyridine reduced stent thrombosis (0.3% vs. 0.7%, hazard ratio [HR]: 0.38, 95% confidence interval [CI]: 0.15 to 0.97; p = 0.04) and MI (2.1% vs. 3.2%, HR: 0.63, 95% CI: 0.44 to 0.91; p = 0.01) versus placebo but did not reduce a composite of death, MI, and stroke (4.3% vs. 4.5%, HR: 0.89, 95% CI: 0.67 to 1.18; p = 0.42), and increased moderate/severe bleeding (2.5% vs. 1.3%, HR: 1.79, 95% CI: 1.15 to 2.80; p = 0.01), and death (2.2% vs. 1.1%, HR: 1.80, 95% CI: 1.11 to 2.92; p = 0.02). Death due to cancer and not related to bleeding was increased (0.64% vs. 0.17%; p = 0.01).In EES-treated subjects, significant reductions in stent thrombosis and MI and an increase in bleeding were observed with continued thienopyridine beyond 1 year compared with aspirin alone. (The Dual Antiplatelet Therapy Study [DAPT Study]); NCT00977938)." @default.
• W2275273709 created "2016-06-24" @default.
• W2275273709 creator A5003831287 @default.
• W2275273709 creator A5008596377 @default.
• W2275273709 creator A5024220356 @default.
• W2275273709 creator A5043568487 @default.
• W2275273709 creator A5053194091 @default.
• W2275273709 creator A5057352435 @default.
• W2275273709 creator A5057974711 @default.
• W2275273709 creator A5060436966 @default.
• W2275273709 creator A5077810268 @default.
• W2275273709 creator A5081743465 @default.
• W2275273709 creator A5082003758 @default.
• W2275273709 creator A5089120659 @default.
• W2275273709 date "2016-01-01" @default.
• W2275273709 modified "2023-09-28" @default.
• W2275273709 title "Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents" @default.
• W2275273709 cites W1756889765 @default.
• W2275273709 cites W2046209971 @default.
• W2275273709 cites W2067955875 @default.
• W2275273709 cites W2076602637 @default.
• W2275273709 cites W2078960594 @default.
• W2275273709 cites W2087150869 @default.
• W2275273709 cites W2096135939 @default.
• W2275273709 cites W2105531921 @default.
• W2275273709 cites W2125173296 @default.
• W2275273709 cites W2136520492 @default.
• W2275273709 cites W2140676515 @default.
• W2275273709 cites W5864417 @default.
• W2275273709 doi "https://doi.org/10.1016/j.jcin.2015.10.001" @default.
• W2275273709 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26793956" @default.
• W2275273709 hasPublicationYear "2016" @default.
• W2275273709 type Work @default.
• W2275273709 sameAs 2275273709 @default.
• W2275273709 citedByCount "50" @default.
• W2275273709 countsByYear W22752737092016 @default.
• W2275273709 countsByYear W22752737092017 @default.
• W2275273709 countsByYear W22752737092018 @default.
• W2275273709 countsByYear W22752737092019 @default.
• W2275273709 countsByYear W22752737092020 @default.
• W2275273709 countsByYear W22752737092021 @default.
• W2275273709 countsByYear W22752737092022 @default.
• W2275273709 countsByYear W22752737092023 @default.
• W2275273709 crossrefType "journal-article" @default.
• W2275273709 hasAuthorship W2275273709A5003831287 @default.
• W2275273709 hasAuthorship W2275273709A5008596377 @default.
• W2275273709 hasAuthorship W2275273709A5024220356 @default.
• W2275273709 hasAuthorship W2275273709A5043568487 @default.
• W2275273709 hasAuthorship W2275273709A5053194091 @default.
• W2275273709 hasAuthorship W2275273709A5057352435 @default.
• W2275273709 hasAuthorship W2275273709A5057974711 @default.
• W2275273709 hasAuthorship W2275273709A5060436966 @default.
• W2275273709 hasAuthorship W2275273709A5077810268 @default.
• W2275273709 hasAuthorship W2275273709A5081743465 @default.
• W2275273709 hasAuthorship W2275273709A5082003758 @default.
• W2275273709 hasAuthorship W2275273709A5089120659 @default.
• W2275273709 hasBestOaLocation W22752737091 @default.
• W2275273709 hasConcept C126322002 @default.
• W2275273709 hasConcept C127413603 @default.
• W2275273709 hasConcept C142724271 @default.
• W2275273709 hasConcept C164705383 @default.
• W2275273709 hasConcept C204787440 @default.
• W2275273709 hasConcept C207103383 @default.
• W2275273709 hasConcept C27081682 @default.
• W2275273709 hasConcept C2777628954 @default.
• W2275273709 hasConcept C2777849778 @default.
• W2275273709 hasConcept C2778583881 @default.
• W2275273709 hasConcept C2779837110 @default.
• W2275273709 hasConcept C2780645631 @default.
• W2275273709 hasConcept C44249647 @default.
• W2275273709 hasConcept C500558357 @default.
• W2275273709 hasConcept C71924100 @default.
• W2275273709 hasConcept C78519656 @default.
• W2275273709 hasConceptScore W2275273709C126322002 @default.
• W2275273709 hasConceptScore W2275273709C127413603 @default.
• W2275273709 hasConceptScore W2275273709C142724271 @default.
• W2275273709 hasConceptScore W2275273709C164705383 @default.
• W2275273709 hasConceptScore W2275273709C204787440 @default.
• W2275273709 hasConceptScore W2275273709C207103383 @default.
• W2275273709 hasConceptScore W2275273709C27081682 @default.
• W2275273709 hasConceptScore W2275273709C2777628954 @default.
• W2275273709 hasConceptScore W2275273709C2777849778 @default.
• W2275273709 hasConceptScore W2275273709C2778583881 @default.
• W2275273709 hasConceptScore W2275273709C2779837110 @default.
• W2275273709 hasConceptScore W2275273709C2780645631 @default.
• W2275273709 hasConceptScore W2275273709C44249647 @default.
• W2275273709 hasConceptScore W2275273709C500558357 @default.
• W2275273709 hasConceptScore W2275273709C71924100 @default.
• W2275273709 hasConceptScore W2275273709C78519656 @default.
• W2275273709 hasIssue "2" @default.
• W2275273709 hasLocation W22752737091 @default.
• W2275273709 hasLocation W22752737092 @default.
• W2275273709 hasOpenAccess W2275273709 @default.
• W2275273709 hasPrimaryLocation W22752737091 @default.
• W2275273709 hasRelatedWork W1972702180 @default.
• W2275273709 hasRelatedWork W2025398624 @default.
• W2275273709 hasRelatedWork W2089715561 @default.
• W2275273709 hasRelatedWork W2117378160 @default.

• next